ÂÜÀòÂÒÂ×

Mr. Daniel Heller is a member of the Board of Directors of Ceptur Therapeutics. He is a General Partner and Chief Investment Officer at Affinity Asset Advisors, a New York-based health care investment fund. Mr. Heller has over 15 years of buy-side and sell-side Biotech investment experience and is currently also a member of the Board of Directors at Kurome Therapeutics. Prior to joining Affinity, Mr. Heller was the Director of Research at Perceptive Advisors, LLC, a Biotechnology analyst at CIBC World Markets, and a venture capital analyst at Paramount Capital Investments. He has also previously held positions at Merck and Pfizer. Mr. Heller earned his BA from the University of Arizona, his MS in Biochemistry from Rutgers University, and his MBA from Cornell University.